Molecular Profiling of Pancreatic Cancer

通过nci -马里兰大学资源合同以及与德国哥廷根大学医学杂志的研究人员的合作，我们从三个不同的患者队列中获得了冷冻胰腺导管腺癌和周围非肿瘤样本。在初步分析中，我们通过微阵列基因表达谱确定了一组基因，这些基因在肿瘤中过表达，并且在两个独立的队列中与较差的生存率相关。我们目前正在使用基于Fluidigm平台的实时定量PCR对基因标记进行技术验证。经过验证和进一步完善的预后基因标记将在第三个独立队列中进行研究，以确认其作为胰腺癌新的预后标记物的效用。我们也在继续努力完成一项方案和问卷，以启动大巴尔的摩地区胰腺癌的病例对照研究，我是这项研究的首席研究员。

Through the NCI-University of Maryland Resource Contract and collaboration with researchers at the Universitatsmedizine Goettingen, Germany, we have obtained frozen pancreatic ductal adenocarcinoma and surrounding nontumor samples from three different patient cohorts. In a preliminary analysis, we have identified a set of genes through microarray gene expression profiling that are overexpressed in tumors and are also associated with poorer survival in two independent cohorts. We are currently performing a technical validation of the gene signature by using quantitative-real time PCR based Fluidigm platform. The validated and further refined prognostic gene signature will be then investigated in the third independent cohort to confirm their utility as novel prognostic marker for pancreatic cancer. We are also continuing our efforts of finalizing a protocol and questionnaire to initiate a case-control study of pancreatic cancer in the greater Baltimore area with myself as the Principal Investigator of this study.